ReviewClinical microbiology reviews2019
Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections.
Review in Clinical microbiology reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07088926 (A Phase IIb Randomized, Double-blind, Placebo-controlled, Parallel, Multidose Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization), which is not on this map. Cited by 497 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase IIb Randomized, Double-blind, Placebo-controlled, Parallel, Multidose Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
Who cites it
497 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Comparison of Ceftolozane-Tazobactam and Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant/Difficult-to-Treat Resistant Pseudomonas aeruginosa Infections: A Systematic Review and Meta-analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Pooled it
- Worldwide threatening prevalence of carbapenem-resistantEpidemiology and infection · 2025Pooled it
- Pooled it
- Genomic and Clinical Features Associated With Reduced Susceptibility to Cefiderocol and Cross-Resistance to β-Lactam/β-Lactamase Inhibitors in a Global Cohort of Pseudomonas aeruginosa.The Journal of infectious diseases · 2026Observational
- Global epidemiology of carbapenem-resistantJAC-antimicrobial resistance · 2026Review
- Molecular and computational analysis of conserved outer membranes (oprI and oprL) in MDR clinical isolates of Pseudomonas aeruginosa as potential vaccine targets from Lahore, Pakistan.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Smaller Genomes and Shorter Prophage Sequences Differentiate Clinical from Environmental Isolates ofbioRxiv : the preprint server for biology · 2026Article
- Targeting Outer Membrane Vesicles ofJournal of microbiology and biotechnology · 2026Review
- In vitro activity of aztreonam-avibactam against carbapenem-resistant Pseudomonas aeruginosa from Southern Brazil.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Real-World Antibiotic Strategies for Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Characterizing the V516M penicillin-binding protein 2 (PBP2) mutation causing zidebactam resistance inAntimicrobial agents and chemotherapy · 2026Article
- Emergence of ceftazidime-avibactam resistance mediated by KPC variants KPC-71 and KPC-78 in ST463Microbiology spectrum · 2026Article
- Prevalence and genotypic distribution of virulence factor genes and antibiotic susceptibility profiles in clinicalMicrobiology spectrum · 2026Article
- Isolation and characterization of bacteriophages against antibiotic-resistanceIranian journal of microbiology · 2026Article
- Rapid microbiological diagnostics for sepsis in critical care: integrating technological advances with antimicrobial stewardship.Acute and critical care · 2026Article
- Successful Rapid Desensitization to Ceftazidime/Avibactam in a Patient With Cystic Fibrosis and Multidrug-ResistantClinical case reports · 2026Article
- Antibiogram and molecular profiling of non-respiratory isolates ofIranian journal of microbiology · 2026Article
- Characterization and comparative genomic analysis of a novel bacteriophage against an extremely drug-resistantMicrobiology spectrum · 2026Article
- Optimisation and validation of capture mNGS for predicting antimicrobial resistance.EBioMedicine · 2026Article
- Genetic and biochemical characterization of OXA-1054, a carbapenem-hydrolyzing class D β-lactamase conferring broad-spectrum β-lactam resistance inAntimicrobial agents and chemotherapy · 2026Article
437 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the worldwide spread of the so-called high-risk clones of multidrug-resistant or extensively drug-resistant (MDR/XDR)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.